Objective To observe the application effect of Baofukang Suppository combined with ozone treatment on high-risk human papilloma virus(HPV)infection in the cervix.Methods A total of 120 patients who were tested positive for HPV in gynecological examination in the Fourth Affiliated Hospital of Nanchang University from March 2018 to December 2020 were selected as research objects,and were divided into experimental group (60 cases)and control group (60 cases)according to random number table method.The control group was treated with Bafukang Suppository,the experimental group was treated with Bafukang Suppository combined with ozone therapy,and the two groups were treated for a total of 3 courses.The clinical efficacy,HPV negative conversion rate,serum tumor necrosis factor α (TNF-α) level,interleukin-6 (IL-6)level,transforming growth factor-β(TGF-β)level and total incidence of adverse reactions were compared between the two groups.Results The total effective rate of experimental group was higher than that of control group,the difference was statistically significant (P<0.05).The negative conversion rate of HR-HPV in experimental groups was higher than that in control group,and the difference was statistically significant (P<0.05).After treatment,the levels of TNF-α and TGF-β in experimental groups were lower than those in control group,and the levels of IL-6 were higher than those in control group,with statistical significances(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion The use of Baofukang Suppository combined with ozone therapy for high-risk cervical HPV patients has a definite effect,can improve the HPV conversion rate,and is relatively safe,which is worthy of clinical promotion and application.
戴 星;孙玉芳;胡 鸣;焦榕芳;张 凡. 保妇康栓联合臭氧治疗宫颈高危型人乳头瘤病毒感染的应用效果[J]. 中国当代医药, 2024, 31(14): 37-40.
DAI Xing SUN Yufang▲ HU Ming JIAO Rongfang ZHANG Fan. Application effect of Baofukang Suppository combined with ozone therapy in the treatment of high-risk cervical human papilloma virus infection. 中国当代医药, 2024, 31(14): 37-40.
Carcea F,Fausto E,Vavoulidis S,et al.Diagnostic performance of HPV E6/E7 mRNA testing towards HPV-DNA testing and p16/Ki67 immunostaining as a biomarker of high-risk HPV recurrence in Greek women surgically treated for their cervical lesions[J].J Obstet Gynaecol Res,2021,47(10):3607-3617.